Julian Little, PhD; Julian P.T. Higgins, PhD; John P.A. Ioannidis, MD, PhD; David Moher, PhD; France Gagnon, PhD; Erik von Elm, MD; Muin J. Khoury, MD, PhD; Barbara Cohen, PhD; George Davey-Smith, MD; Jeremy Grimshaw, MBChB, PhD; Paul Scheet, PhD; Marta Gwinn, MD; Robin E. Williamson, PhD; Guang Yong Zou, PhD; Kim Hutchings, MSc; Candice Y. Johnson, MSc; Valerie Tait, PhD; Miriam Wiens, MSc; Jean Golding, DSc; Cornelia van Duijn, PhD; John McLaughlin, PhD; Andrew Paterson, MD; George Wells, PhD; Isabel Fortier, PhD; Matthew Freedman, MD; Maja Zecevic, PhD; Richard King, MD, PhD; Claire Infante-Rivard, MD, PhD; Alex Stewart, PhD; Nick Birkett, MD
Acknowledgment: The authors thank Kyle Vogan and Allen Wilcox for their participation in the workshop and for their comments; Michele Cargill (Affymetrix) and Aaron del Duca (DNA Genotek) for their participation in the workshop as observers; and the Public Population Project in Genomics (P3G), hosted by the University of Montreal and supported by Genome Canada and Genome Quebec. This article was made possible thanks to input and discussion by the P3G International Working Group on Epidemiology and Biostatistics, discussion held in Montreal, May 2007. The authors also thank the reviewers for their very thoughtful feedback, and Silvia Visentin, Rob Moriarity, Morgan Macneill, and Valery L'Heureux for administrative support. We were unable to contact Barbara Cohen to confirm her involvement in the latest version of this article.
Note: Julian Little holds a Canada Research Chair in Human Genome Epidemiology; France Gagnon holds a Canadian Institutes for Health Research New Investigator Award and a Canada Research Chair in Genetic Epidemiology; Jeremy Grimshaw holds a Canada Research Chair in Health Knowledge Transfer and Uptake; Andrew Paterson holds a Canada Research Chair in Genetics of Complex Diseases; and Claire Infante-Rivard holds a Canada Research Chair and is James McGill Professor at McGill University.
Grant Support: By the Institutes of Genetics and of Nutrition, Metabolism and Diabetes, Canadian Institutes of Health Research; Genome Canada; Biotechnology, Genomics and Population Health Branch, Public Health Agency of Canada; Affymetrix; DNA Genotek; TrialStat!; and GeneSens. The funders had no role in the decision to submit the article or in its preparation.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Julian Little, PhD, University of Ottawa, 451 Smyth Road, Ottawa, Ontario K1H 8M5, Canada; e-mail, firstname.lastname@example.org.
Current Author Addresses: Dr. Little: Department of Epidemiology and Community Medicine, University of Ottawa, 451 Smyth Road, Ottawa, Ontario K1H 8M5, Canada.
Dr. Higgins: MRC Biostatistics Unit, Institute of Public Health, Forvie Site, Robinson Way, Cambridge CB2 0SR, United Kingdom.
Dr. Ioannidis: Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina 45110, Greece.
Dr. Moher: Department of Epidemiology and Community Medicine, University of Ottawa, 451 Smyth Road, Ottawa, Ontario K1H 8M5, Canada.
Dr. Gagnon: Dalla Lana School of Public Health, University of Toronto, 155 College Street, Toronto, Ontario M5T 3M7, Canada.
Dr. von Elm: Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland.
Dr. Khoury: National Office of Public Health Genomics, Centers for Disease Control & Prevention, 1600 Clifton Road, Atlanta, GA 30333.
Dr. Cohen: Public Library of Science, 185 Berry Street, San Francisco, CA 94107.
Dr. Cohen: former Senior Editor, Public Library of Science, Public Library of Science, 185 Berry Street, Suite 3100, San Francisco, CA 94107.
Dr. Davey-Smith: MRC Centre for Cal Analyses in Translational Epidemiology, Department of Social Medicine, University of Bristol, Oakfield House, Oakfield Grove, Clifton, Bristol BS8 2BN, United Kingdom.
Dr. Grimshaw: Clinical Epidemiology Program, Ottawa Health Research Institute, Department of Medicine, Centre for Best Practice, University of Ottawa, The Ottawa Hospital–Civic Site, 1053 Carling Avenue, C-404, Ottawa, Ontario K1Y 4E9, Canada.
Dr. Scheet: University of Texas, MD Anderson Cancer Center, Department of Computational Genetic Epidemiology, 1155 Pressler Boulevard, Unit 1340, Houston, TX 77030.
Dr. Gwinn: National Office of Public Health Genomics, Centers for Disease Control & Prevention, 1600 Clifton Road, Atlanta, GA 30333.
Dr. Williamson: American Journal of Human Genetics, 77 Avenue Louis Paseur, NRB160C, Boston, MA 02115.
Dr. Zou: Department of Epidemiology and Biostatistics, University of Western Ontario, KB 201, Kresge Building, UWO, London, Ontario N6A 5C1, Canada.
Ms. Hutchings, Ms. Johnson, Dr. Tate, Ms. Wiens, and Dr. Birkett: Department of Epidemiology and Community Medicine, University of Ottawa, 451 Smyth Road, Ottawa, Ontario K1H 8M5, Canada.
Dr. Golding: Paediatric and Perinatal Epidemiology, Centre for Child and Adolescent Health, Department of Community Based Medicine, University of Bristol, Barley House, Oakfield Grove, Bristol BS8 2BN, United Kingdom.
Dr. van Duijn: European Journal of Epidemiology, PO Box 2040, 3000 CA, Rotterdam, Netherlands.
Dr. McLaughlin: Cancer Care Ontario, Toronto, and Prosserman Centre for Health Research at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Ave, Toronto, Ontario M5G 1X5, Canada.
Dr. Paterson: The Centre for Applied Genomics, The Hospital for Sick Children, MaRS Centre–East Tower, 101 College Street, Room 15-707, Toronto, Ontario M5G 1L7, Canada.
Dr. Wells: Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada.
Dr. Fortier: Genome Quebec & P3G Observatory, 3333 Queen Mary Road, Suite 590, Montréal, Québec H3V 1A2, Canada.
Dr. Freedman: Dana-Farber Cancer Institute, Massachusetts General Hospital, 44 Binney Street, Mailstop: Dana, 710C, Boston, MA 02115.
Dr. Zecevic: The Lancet, 360 Park Avenue South, New York, NY 10010-1710.
Dr. King: University of Minnesota, MMC 485, 420 Washington Avenue, Minneapolis, MN 55455.
Dr. Infante-Rivard: McGill University, Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine, 1130 Pine Avenue West, Montréal, Quebec H3A 1A3, Canada.
Dr. Stewart: University of Ottawa Heart Institute, 40 Ruskin Street, Room H3100, Ottawa, Ontario K1Y 4W7, Canada.
Little J., Higgins J., Ioannidis J., Moher D., Gagnon F., von Elm E., Khoury M., Cohen B., Davey-Smith G., Grimshaw J., Scheet P., Gwinn M., Williamson R., Zou G., Hutchings K., Johnson C., Tait V., Wiens M., Golding J., van Duijn C., McLaughlin J., Paterson A., Wells G., Fortier I., Freedman M., Zecevic M., King R., Infante-Rivard C., Stewart A., Birkett N.; STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement. Ann Intern Med. 2009;150:206-215. doi: 10.7326/0003-4819-150-3-200902030-00011
Download citation file:
Published: Ann Intern Med. 2009;150(3):206-215.
Making sense of rapidly evolving evidence on genetic associations is crucial to making genuine advances in human genomics and the eventual integration of this information into the practice of medicine and public health. Assessment of the strengths and weaknesses of this evidence, and hence the ability to synthesize it, has been limited by inadequate reporting of results. The STrengthening the REporting of Genetic Association studies (STREGA) initiative builds on the STrengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement and provides additions to 12 of the 22 items on the STROBE checklist. The additions concern population stratification, genotyping errors, modeling haplotype variation, Hardy-Weinberg equilibrium, replication, selection of participants, rationale for choice of genes and variants, treatment effects in studying quantitative traits, statistical methods, relatedness, reporting of descriptive and outcome data, and issues of data volume that are important to consider in genetic association studies. The STREGA recommendations do not prescribe or dictate how a genetic association study should be designed but seek to enhance the transparency of its reporting, regardless of choices made during design, conduct, or analysis.
The rapidly evolving evidence on genetic associations is crucial to integrating human genomics into the practice of medicine and public health (1, 2). Genetic factors are likely to affect the occurrence of numerous common diseases, and therefore identifying and characterizing the associated risk (or protection) will be important in improving the understanding of etiology and potentially for developing interventions based on genetic information. The number of publications on the associations between genes and diseases has increased tremendously; with more than 34 000 published articles, the annual number has more than doubled between 2001 and 2008 (3, 4). Articles on genetic associations have been published in about 1500 journals and in several languages.
Despite the many similarities between genetic association studies and “classical” observational epidemiologic studies (that is, cross-sectional, case–control, and cohort) of lifestyle and environmental factors, genetic association studies present several specific challenges, including an unprecedented volume of new data (5, 6) and the likelihood of very small individual effects. Genes may operate in complex pathways with gene–environment and gene–gene interactions (7). Moreover, the current evidence base on gene–disease associations is fraught with methodological problems (8–10). Inadequate reporting of results, even from well-conducted studies, hampers assessment of a study's strengths and weaknesses and hence the integration of evidence (11).
Although several commentaries on the conduct, appraisal, and/or reporting of genetic association studies have so far been published (12–39), their recommendations differ. For example, some papers suggest that replication of findings should be part of the publication (12, 13, 16, 17, 23, 26, 34–36), whereas others consider this suggestion unnecessary or even unreasonable (21, 40–44). In many publications, the guidance has focused on genetic association studies of specific diseases (14, 15, 17, 19, 22, 23, 25, 26, 31–38) or the design and conduct of genetic association studies (13–15, 17, 19, 20, 22, 23, 25, 30–32, 35, 36) rather than on the quality of the reporting.
Despite increasing recognition of these problems, the quality of reporting genetic association studies needs to be improved (45–49). For example, an assessment of a random sample of 315 genetic association studies published from 2001 to 2003 found that most studies provided some qualitative descriptions of the study participants (for example, origin and enrollment criteria), but reporting of quantitative descriptors, such as age and sex, was variable (49). In addition, completeness of reporting of methods that allow readers to assess potential biases (for example, number of exclusions or number of samples that could not be genotyped) varied (49). Only some studies described methods to validate genotyping or mentioned whether research staff were blinded to outcome. The same problems persisted in a smaller sample of studies published in 2006 (49). Lack of transparency and incomplete reporting have raised concerns in a range of health research fields (11, 50–53), and poor reporting has been associated with biased estimates of effects in clinical intervention studies (54).
The main goal of this article is to propose and justify a set of guiding principles for reporting results of genetic association studies. The epidemiology community has recently developed the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) Statement for cross-sectional, case–control, and cohort studies (55, 56). Given the relevance of general epidemiologic principles for genetic association studies, we propose recommendations in an extension of the STROBE Statement called the STrengthening the REporting of Genetic Association studies (STREGA) Statement. The recommendations of the STROBE Statement have a strong foundation because they are based on empirical evidence on the reporting of observational studies, and they involved extensive consultations in the epidemiologic research community (56). We have sought to identify gaps and areas of controversy in the evidence regarding potential biases in genetic association studies. With the recommendations, we have indicated available empirical or theoretical work that has demonstrated or suggested that a methodological feature of a study can influence the direction or magnitude of the association observed. We acknowledge that for many items, no such evidence exists. The intended audience for the reporting guideline is broad and includes epidemiologists, geneticists, statisticians, clinician scientists, and laboratory-based investigators who undertake genetic association studies. In addition, it includes “users” of such studies who wish to understand the basic premise, design, and limitations of genetic association studies in order to interpret the results. The field of genetic associations is evolving very rapidly with the advent of genome-wide association investigations, high-throughput platforms assessing genetic variability beyond common single-nucleotide polymorphisms (SNPs) (for example, copy number variants, rare variants), and eventually routine full sequencing of samples from large populations. Our recommendations are not intended to support or oppose the choice of any particular study design or method. Instead, they are intended to maximize the transparency, quality, and completeness of reporting what was done and found in a particular study.
A multidisciplinary group developed the STREGA Statement by using literature review, workshop presentations and discussion, and iterative electronic correspondence after the workshop. Thirty-three of 74 invitees participated in the STREGA workshop in Ottawa, Ontario, Canada, in June 2006. Participants included epidemiologists, geneticists, statisticians, journal editors, and graduate students.
Before the workshop, an electronic search was performed to identify existing reporting guidance for genetic association studies. Workshop participants were also asked to identify any additional guidance. They prepared brief presentations on existing reporting guidelines, empirical evidence on reporting of genetic association studies, the development of the STROBE Statement, and several key areas for discussion that were identified on the basis of consultations before the workshop. These areas included the selection and participation of study participants, rationale for choice of genes and variants investigated, genotyping errors, methods for inferring haplotypes, population stratification, assessment of Hardy-Weinberg equilibrium (HWE), multiple testing, reporting of quantitative (continuous) outcomes, selectively reporting study results, joint effects, and inference of causation in single studies. Additional resources to inform workshop participants were the HuGENet handbook (57, 58), examples of data extraction forms from systematic reviews or meta-analyses, articles on guideline development (59, 60), and the checklists developed for STROBE. To harmonize our recommendations for genetic association studies with those for observational epidemiologic studies, we communicated with the STROBE group during the development process and sought their comments on the STREGA draft documents. We also provided comments on the developing STROBE Statement and its associated explanation and elaboration document (56).
In the Table, we present the STREGA recommendations, an extension to the STROBE checklist (55) for genetic association studies. The resulting STREGA checklist provides additions to 12 of the 22 items on the STROBE checklist. During the workshop and subsequent consultations, we identified 5 main areas of special interest that are specific to, or especially relevant in, genetic association studies: genotyping errors, population stratification, modeling haplotype variation, HWE, and replication. We elaborate on each of these areas, starting each section with the corresponding STREGA recommendation, followed by a brief outline of the issue and an explanation for the recommendations. Complementary information on these areas and the rationale for additional STREGA recommendations relating to selection of participants, choice of genes and variants investigated, treatment effects in studying quantitative traits, statistical methods, relatedness, reporting of descriptive and outcome data, and issues of data volume, are presented in the Appendix Table.
Recommendation for reporting of methods (Table, item 8[b]: Describe laboratory methods, including source and storage of DNA, genotyping methods and platforms (including the allele-calling algorithm used and its version), error rates, and call rates. State the laboratory/center where genotyping was done. Describe comparability of laboratory methods if there is more than one group. Specify whether genotypes were assigned using all of the data from the study simultaneously or in smaller batches.
Recommendation for reporting of results (Table, item 13[a]): Report numbers of individuals in whom genotyping was attempted and numbers of individuals in whom genotyping was successful.
Genotyping errors can occur as a result of effects of the DNA sequence flanking the marker of interest; poor quality or quantity of the DNA extracted from biological samples; biochemical artifacts; poor equipment precision or equipment failure; or human error in sample handling, conduct of the array, or handling the data obtained from the array (61). A commentary published in 2005 on the possible causes and consequences of genotyping errors observed that an increasing number of researchers were aware of the problem, but that the effects of such errors had largely been neglected (61). The magnitude of genotyping errors has been reported to vary between 0.5% and 30% (61–64). In high-throughput centers, an error rate of 0.5% per genotype has been observed for blind duplicates that were run on the same gel (64). This lower error rate reflects an explicit choice of markers for which genotyping rates have been found to be highly repeatable and whose individual polymerase chain reactions (PCRs) have been optimized. Nondifferential genotyping errors, that is, those that do not differ systematically according to outcome status, will usually bias associations toward the null (65, 66), just as for other nondifferential errors. The most marked bias occurs when genotyping sensitivity is poor and genotype prevalence is high (>85%) or, as the corollary, when genotyping specificity is poor and genotype prevalence is low (<15%) (65). When measurement of the environmental exposure has substantial error, genotyping errors of the order of 3% can lead to substantial underestimation of the magnitude of an interaction effect (67). When there are systematic differences in genotyping according to outcome status (differential error), bias in any direction may occur. Unblinded assessment may lead to differential misclassification. For genome-wide association studies of SNPs, differential misclassification between comparison groups (for example, cases and controls) can occur because of differences in DNA storage or in collection or processing protocols, even when the genotyping itself meets the highest possible standards (68). In this situation, using samples blinded to comparison group to determine the parameters for allele calling could still lead to differential misclassification. To minimize such differential misclassification, it would be necessary to calibrate the software separately for each group. This is one of the reasons for our recommendation to specify whether genotypes were assigned using all of the data from the study simultaneously or in smaller batches.
Recommendation for reporting of methods (Table, item 12[h]): Describe any methods used to assess or address population stratification.
Population stratification is the presence within a population of subgroups among which allele (or genotype, or haplotype) frequencies and disease risks differ. When the groups compared in the study differ in their proportions of the population subgroups, an association between the genotype and the disease being investigated may reflect the genotype being an indicator identifying a population subgroup rather than a causal variant. In this situation, the population subgroup is a confounder because it is associated with both genotype frequency and disease risk. The potential implications of population stratification for the validity of genetic association studies have been debated (69–83). Modeling the possible effect of population stratification (when no effort has been made to address it) suggests that the effect is likely to be small in most situations (75, 76, 78–80). Meta-analyses of 43 gene–disease associations comprising 697 individual studies showed consistent associations across groups of different ethnic origin (80) and thus provide evidence against a large effect of population stratification, hidden or otherwise. However, as studies of association and interaction typically address moderate or small effects and hence require large sample sizes, a small bias arising from population stratification may be important (81). Study design (case-family control studies) and statistical methods (84) have been proposed to address population stratification, but so far few studies have used these suggestions (49). Most of the early genome-wide association studies used family-based designs or such methods as genomic control and principal components analysis (85, 86) to control for stratification. These approaches are particularly appropriate for addressing bias when the identified genetic effects are very small (odds ratio, <1.20), as has been the situation in many recent genome-wide association studies (85, 87–105). In view of the debate about the potential implications of population stratification for the validity of genetic association studies, we recommend transparent reporting of the methods used, or stating that none was used, to address this potential problem. This reporting will enable empirical evidence to accrue about the effects of population stratification and methods to assess it.
Recommendation for reporting of methods (Table, item 12[g]): Describe any methods used for inferring genotypes or haplotypes.
A haplotype is a combination of specific alleles at neighboring genes that tends to be inherited together. There has been considerable interest in modeling haplotype variation within candidate genes. Typically, the number of haplotypes observed within a gene is much smaller than the theoretical number of all possible haplotypes (106, 107). Motivation for utilizing haplotypes comes, in large part, from the fact that multiple SNPs may “tag” an untyped variant more effectively than a single-typed variant. The subset of SNPs used in such an approach is called “haplotype-tagging” SNPs. Implicitly, an aim of haplotype tagging is to reduce the number of SNPs that have to be genotyped, while maintaining statistical power to detect an association with the phenotype. Maps of human genetic variation are becoming more complete, and large-scale genotypic analysis is becoming increasingly feasible. In consequence, it is possible that modeling haplotype variation will become more focused on rare causal variants because these may not be included in the genotyping platforms.
In most current, large-scale genetic association studies, data are collected as unphased multilocus genotypes (that is, which alleles are aligned together on particular segments of a chromosome is unknown). It is common in such studies to use statistical methods to estimate haplotypes (108–111), and their accuracy and efficiency have been discussed (112–116). Some methods attempt to make use of a concept called haplotype “blocks” (117, 118), but the results of these methods are sensitive to the specific definitions of the “blocks” (119, 120). Reporting of the methods used to infer individual haplotypes and population haplotype frequencies, along with their associated uncertainties, should enhance our understanding of the possible effects of different methods of modeling haplotype variation on study results as well as enabling comparison and syntheses of results from different studies.
Information on common patterns of genetic variation revealed by the International Haplotype Map (HapMap) Project (108) can be applied in the analysis of genome-wide association studies to infer genotypic variation at markers not typed directly in these studies (121, 122). Essentially, these methods perform haplotype-based tests but make use of information on variation in a set of reference samples (for example, HapMap) to guide the specific tests of association, collapsing a potentially large number of haplotypes into 2 classes (the allelic variation) at each marker. It is expected that these techniques will increase power in individual studies and will aid in combining data across studies and even across differing genotyping platforms. If imputation procedures have been used, it is useful to know the method, accuracy thresholds for acceptable imputation, how imputed genotypes were handled or weighted in the analysis, and whether any associations based on imputed genotypes were also verified on the basis of direct genotyping at a subsequent stage.
Recommendation for reporting of methods (Table, item 12[f]): State whether Hardy-Weinberg equilibrium was considered and, if so, how.
Hardy-Weinberg equilibrium has become widely accepted as an underlying model in population genetics after Hardy (123) and Weinberg (124) proposed the concept that genotype frequencies at a genetic locus are stable within 1 generation of random mating; the assumption of HWE is equivalent to the independence of 2 alleles at a locus. Views differ on whether testing for departure from HWE is a useful method to detect errors or peculiarities in the data set, and also the method of testing (125). In particular, it has been suggested that deviation from HWE may be a sign of genotyping errors (126–128). Testing for departure from HWE has a role in detecting gross errors of genotyping in large-scale genotyping projects, such as identifying SNPs for which the clustering algorithms used to call genotypes have broken down (85, 129). However, the statistical power to detect less important errors of genotyping by testing for departure from HWE is low (130), and in hypothetical data, the presence of HWE was generally not altered by the introduction of genotyping errors (131). Furthermore, the assumptions underlying HWE, including random mating, lack of selection according to genotype, and absence of mutation or gene flow, are rarely met in human populations (132, 133). In 5 of 42 gene–disease associations assessed in meta-analyses of almost 600 studies, the results of studies that violated HWE significantly differed from results of studies that conformed to the model (134). Moreover, the study suggested that exclusion of HWE-violating studies may result in loss of the statistical significance of some postulated gene–disease associations and that adjustment for the magnitude of deviation from the model may also have the same consequence for other gene–disease associations. Given the differing views about the value of testing for departure from HWE and about the test methods, transparent reporting of whether such testing was done and, if so, the method used, is important for allowing the empirical evidence to accrue.
For massive-testing platforms, such as genome-wide association studies, it might be expected that many false-positive violations of HWE would occur if a lenient P value threshold were set. There is no consensus on the appropriate P value threshold for HWE-related quality control in this setting. So, we recommend that investigators state which threshold they have used, if any, to exclude specific polymorphisms from further consideration. For SNPs with low minor allele frequencies, substantially more significant results than expected by chance have been observed, and the distribution of alleles at these loci has often been found to show departure from HWE.
For genome-wide association studies, another approach that has been used to detect errors or peculiarities in the data set (due to population stratification, genotyping error, HWE deviations or other reasons) has been to construct quantile-quantile (Q/Q) plots whereby observed association statistics or calculated P values for each SNP are ranked in order from smallest to largest and plotted against the expected null distribution (129, 130). The shape of the curve can lend insight into whether systematic biases are present.
Recommendation: State if the study is the first report of a genetic association, a replication effort, or both (Table, item 3).
Articles that present and synthesize data from several studies in a single report are becoming more common. In particular, many genome-wide association analyses describe several different study populations, sometimes with different study designs and genotyping platforms, and in various stages of discovery and replication (129, 130). When data from several studies are presented in a single original report, each of the constituent studies and the composite results should be fully described. For example, a discussion of sample size and the reason for arriving at that size would include clear differentiation between the initial group (those that were typed with the full set of SNPs) and those that were included in the replication phase only (typed with a reduced set of SNPs) (129, 130). Describing the methods and results in sufficient detail would require substantial space in print, but options for publishing additional information on the study online make this possible.
The choices made for study design, conduct, and data analysis potentially influence the magnitude and direction of results of genetic association studies. However, the empirical evidence on these effects is insufficient. Transparency of reporting is thus essential for developing a better evidence base (Appendix Table). Transparent reporting helps address gaps in empirical evidence (45), such as the effects of incomplete participation and genotyping errors. It will also help assess the impact of currently controversial issues, such as population stratification, methods of inferring haplotypes, departure from HWE, and multiple testing on effect estimates under different study conditions.
The STREGA Statement proposes a minimum checklist of items for reporting genetic association studies. The statement has several strengths. First, it is based on existing guidance on reporting observational studies (STROBE). Second, it was developed from discussions of an interdisciplinary group that included epidemiologists, geneticists, statisticians, journal editors, and graduate students, thus reflecting a broad collaborative approach in terminology accessible to scientists from diverse disciplines. Finally, it explicitly describes the rationale for the decisions (Appendix Table) and has a clear plan for dissemination and evaluation.
The STREGA recommendations are available at http://www.strega-statement.org. We welcome comments, which will be used to refine future versions of the recommendations. We note that little is known about the most effective ways to apply reporting guidelines in practice, and that therefore it has been suggested that editors and authors collect, analyze, and report their experiences in using such guidelines (135). We consider that the STREGA recommendations can be used by authors, peer reviewers, and editors to improve the reporting of genetic association studies. We invite journals to endorse STREGA, for example, by including STREGA and its Web address in their Instructions for Authors and by advising authors and peer reviewers to use the checklist as a guide. It has been suggested that reporting guidelines are most helpful if authors keep the general content of the guideline items in mind as they write their initial drafts, then refer to the details of individual items as they critically appraise what they have written during the revision process (135). We emphasize that the STREGA reporting guidelines should not be used for screening submitted manuscripts to determine the quality or validity of the study being reported. Adherence to the recommendations may make some manuscripts longer, and this may be seen as a drawback in an era of limited space in a print journal. However, the ability to post information on the Web should alleviate this concern. The place in which supplementary information is presented can be decided by the authors and editors of the individual journal.
We hope that the recommendations stimulate transparent and improved reporting of genetic association studies. In turn, better reporting of original studies would facilitate the synthesis of available research results and the further development of study methods in genetic epidemiology with the ultimate goal of improving the understanding of the role of genetic factors in the cause of diseases.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Cardiology, Hematology/Oncology, Hospital Medicine, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only